The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly sophisticated vectors to deliver payloads that could reverse the effects of diseases. However, in the transition to in vivo applications many approaches still fail in their attempt to effectively reach target tissues or cells.
Metagenomi Inc. has reported new dose-range-finding data from its MGX-001 hemophilia A program. MGX-001 is designed to provide curative, life-long protection from bleeding events and joint damage in adults and children with hemophilia A.
City Therapeutics Inc. has submitted a clinical trial application (CTA) to the U.K. Medicines and Healthcare Products Regulatory Agency (MHRA) to initiate a phase I study of CITY-FXI, an investigational RNAi therapeutic targeting factor XI (FXI) for the treatment of thromboembolic diseases.
Simcere Pharmaceutical Co. Ltd. has described stachybotrys microspore triprenyl phenols (SMTPs) acting as plasminogen activators reported to be useful for the treatment of thromboembolism.
Alethio Therapeutics (formerly known as Alethiomics Ltd.) has emerged from stealth with two antibody-drug conjugate (ADC) programs for the treatment of myeloproliferative neoplasms (MPNs).
A technology that combines transcriptomic data and AI enables a novel approach to drug discovery based on the state of cells, how they behave and which genes they express. The Drugreflector model, developed by scientists at Cellarity Inc., learns from gene expression profiles and predicts which compounds could induce beneficial changes in that cellular state to develop a treatment.
Sickle cell disease (SCD) is a genetic disorder caused by a single point mutation in the β-globin gene, leading to the production of abnormal hemoglobin. Patients with SCD lacking a compatible donor for allogeneic hematopoietic stem/progenitor cell transplantation can benefit from gene therapy approaches.
Entasis Therapeutics Holdings Inc. has described mannan-binding lectin serine protease 2 (MASP2) and/or mannan-binding lectin serine protease 3 (MASP3) inhibitors reported to be useful for the treatment of thrombotic microangiopathy, ischemia-reperfusion injury, disseminated intravascular coagulation, graft-versus-host disease, diffuse alveolar hemorrhage syndrome, and renal, eye and cardiovascular disorders, among others.
While recent advances in gene therapy have offered unprecedented options for patients with hemophilia, new data presented at the 32nd Annual Congress of the European Society of Gene and Cell Therapy (ESGCT), held in Seville Oct. 7-10, revealed persistent concerns regarding the durability of these treatments and their potential liver toxicity.
The transition from complex and costly ex vivo strategies to platforms that enable direct cellular intervention within the body, known as in vivo therapies, is marking a paradigm change in the field of gene and cell therapies by simplifying manufacturing, improving tissue targeting and expanding clinical access to treatments.
RSS
